Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — Biotech Showcase San Francisco (December 2016)
17 slides from Xbrane Biopharma AB's conference presentation, Dec 15, 2016
Slide 1: Investor presentation Xbrane Biopharma AB
P I O N EERIN G HIGH D EMA N D COMPL EX GENERICS Investor presentation XBRANE BIOPHARMA AB (publ) VATO R S EC U R I T I E S REGUL ATED BY THE SWEDISH FSA
Slide 2: Xbrane develops biosimilars and generic long acting injectables
XBRANE DEVELOPS BIOSIMILARS AND GENERIC LONG ACTING INJECTABLES First wave targets XLUCANE Second wave targets 100 BEUR » Patented low-cost technology » Originator sales 3,6 BUSD SPHEROTIDE 80 BEUR » Launch Iran 2017 » Worlds first generic » Launch EU/US 2022/2020 » Originator sales 0,5 BUSD 30 BEUR
Slide 3: Xbrane has long experience from service delivery to leading pharma companies
XBRANE HAS LONG EXPERIENCE FROM SERVICE DELIVERY TO LEADING PHARMA COMPANIES XBRANE - SWEDEN SELECTED CUSTOMERS ‣ Founded 2008 at institute of membrane technology at Stockholm University ‣ Based on unique patented high-yield protein expression technology ‣ R&D service and technology out-licensing ‣
Slide 4: Xbrane has R&D teams with deep expertise in Sweden and Italy
XBRANE HAS R&D TEAMS WITH DEEP EXPERTIESE IN SWEDEN AND ITALY XBRANE SWEDEN XBRANE ITALY ‣ Team of 10 scientists ‣ Team of 5 scientists ‣ Biosimilar development laboratory with ‣ Deep expertise and know how state-of-the-art upstream and in PLGA microspheres downstream equipment ‣ Dedicated commercia
Slide 5: Xbrane is listed at Nasdaq First North
XBRANE IS LISTED AT NASDAQ FIRST NORTH ‣ IPO of 12 MUSD in Feb 2016 ‣ Market cap: 20 MUSD ‣ Largest IPO in Europe beginning of 2016 ”There has not been a single US initial public offering this year according to Dealogic, while just $31m has priced for European exchanges, with a $12m deal from Swedis
Slide 6: Spherotide: world's first generic to 0.5 BUSD prostate cancer drug
SPHEROTIDE: WORLDS FIRST GENERIC TO 0,5 BUSD PROSTATE CANCER DRUG OVERVIEW TECHNOLOGY ‣Product: Worlds first generic to long acting ‣ Encapsulation of API in PLGA microspheres triptorelin ‣Indication: Prostate cancer, endometriosis, uterine fibroids Americas ‣Originator sales: 0,5 B USD Middle East
Slide 7: Spherotide: annual sales potential estimated to +150 MUSD
SPHEROTIDE: ANNUAL SALES POTENTIAL ESTIMATED TO +150 M USD Legend Russia Originator annual sales Europe 8 MUSD Spherotide annual sales potential 250 MUSD 3 MUSD Launch 65 MUSD 2019 2019 Out-licensing ongoing North America Out-licensing ongoing 35 MUSD 15 MUSD Iran China 2019 MENA (excl. Iran) 30 MUS
Slide 8: Xlucane: world's most cost efficient ranibizumab biosimilar
XLUCANE: WORLDS MOST COST EFFICIENT RANIBIZUMAB BIOSIMILAR OVERVIEW BIOSIMILARITY Primary and higher order structure: Identical ‣ Product: Ranibizumab (Lucentis) biosimilar CD, peptide map, cIEF, HPLC ‣Originator sales: 3,6 BUSD Americas ‣ Indications: Wet Age related Macular Degeneration, Diabetic
Slide 9: Xlucane: patented technology up to 8x as productive in production of proteins
XLUCANE: PATENTED TECHNOLOGY UP TO 8X AS PRODUCTIVE IN PRODUCTION OF PROTEINS PATENTED TECHNOLOGY: REGULATING PRODUCTION RESULTS: +8X MORE PRODUCTIVE AND UP TO 85% LOWER INTENSITY IN E.COLI INCREASE OVERALL PRODUCTION COST VS. STANDARD SYSTEMS PRODUCTIVITY Lite Optimal socker Mycket socker- tillsatt
Slide 10: Xlucane: addresses a biosimilar market estimated to +1.2 BUSD
XLUCANE: ADRESSES A BIOSIMILAR MARKET ESTIMATED TO +1,2 B USD Russia Legend Europe 40 MUSD Originator annual sales 1,5 BUSD 15 MUSD Estimated biosimilar market* 400 MUSD 2020 Launch 2022 Out-licensing ongoing North America Out-licensing ongoing China 1,7 BUSD <100 MUSD Iran 50 MUSD Japan 700 MUSD ME
Slide 11: 2017 will be an exciting year for Xbrane
2017 WILL BE AN EXITING YEAR FOR XBRANE Q3: Out-licensing in Europe Q3: Initiation clinical studies Q1: Out-licensing in China Q1: GMP approval Q4: Launch in facility Iran Q1: First sales to partner in Iran Q4: Out-licensing global Q4: Initiation clinical studies
Slide 12: Xbrane develops biosimilars and generic long acting injectables
XBRANE DEVELOPS BIOSIMILARS AND GENERIC LONG ACTING INJECTABLES First wave targets Second wave targets 100 BEUR 80 BEUR 30 BEUR Total sales of off-patent originator drugs 2,5 BEUR 2,5 Total sales of BEUR biosimilars and generics 2008 2015 2020 2025
Slide 13: Thank you
THANK YOU ‣ Subscribe to newsletter: www.xbrane.com
Slide 14: Appendix
APPENDIX XUBRANE
Slide 15: Xbrane has a portfolio of potential candidates addressing a +10 B USD market
XBRANE HAS A PORTFOLIO OF POTENTIAL CANDIDATES ADRESSING A +10 B USD MARKET Launch in emerging markets Process GMP Comparative Market Global sales Primary patent development Production clinical trial registration Original drug Active substance Indication (M USD) expiry Spherotide 2016 2017/2018 2019
Slide 16: Board of directors
BOARD OF DIRECTORS SAEID ESMAEILZADEH ALESSANDRO SIDOLI GIORGIO CHIRIVI PETER EDMAN KARIN WINGSTRAND MARIS HARTMANIS Ph.D, Chairman of the board Non-executive director Non-executive director Ph.D, Non-executive director M.Sc, Non-executive Ph.D, Non-executive director director • Professor in Materia
Slide 17: Management team
MANAGEMENT TEAM MARTIN ÅMARK SIAVASH BASHIRI PAOLO SARMIENTOS DAVID VIKSTRÖM CARLO COLOMBO CEO Head of Biosimilars Head of slow release CTO Head of production generics • MSc in Industrial Engineering and • M Sc. in Molecular • Ph.D. in ”expression • Ph. D in Industrial Management from Lith biotechno
Xbrane Biopharma — Biotech Showcase San Francisco (December 2016) on 6ix